- Price
- $2.08
- Day
- -5.88%
- Mkt Cap
- $87.85M
- 52W Range
- $1.13 – $2.89
- Volume
- 307.8K
- Beta
- 0.28
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Deutsche Bank AG purchased a new stake in Pulmonx Corporation (NASDAQ: LUNG) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 402,316 shares of the company's stock, valued at approximately $523,000. Deutsche Bank AG owned approximately 0.94% of
Read full article
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.
Read full article
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
Read full article
After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Read full article